Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares
The gross proceeds to Larimar, before deducting the underwriting discounts and commissions and estimated offering expenses, were approximately $80.5 million.
- The gross proceeds to Larimar, before deducting the underwriting discounts and commissions and estimated offering expenses, were approximately $80.5 million.
- Guggenheim Securities, LLC acted as lead book-running manager for the offering and William Blair & Company, L.L.C.
- The shares were offered by Larimar pursuant to an effective shelf registration statement on Form S-3 (File No.
- Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases.